9 completed, 1 recruiting, 1 withdrawn. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 9, Recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Porphyrias: new trials by email Literature Review of Porphyrias trials Research Report on Porphyrias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP ATL-001 (Ciclopirox oral solution) - Congenital Erythropoietic Porphyria (CEP) | Phase 1 / Phase 2 | Recruiting | Atlas Molecular Pharma | 6 | 2026-01-29 | 2026-03-24 |
| Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline bitopertin - Protoporphyria | Phase 1 | Withdrawn | Wake Forest University Health Sciences | 2026-01-01 | 2026-01-29 | |
| Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients Afamelanotide 16mg implant - Erythropoietic Protoporphyria | Phase 1 / Phase 2 | Completed | Clinuvel Europe Limited | 28 | 2024-03-07 | 2026-07-27 |
| A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP) Givosiran, 5-probe cocktail - Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP) | Phase 1 | Completed | Alnylam Pharmaceuticals | 10 | 2018-04-26 | 2019-03-12 |
| Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride Chlorpromazine Hydrochloride - Anti-Psychotic, Management of Manifestations of Psychotic Disorders | Phase 1 | Completed | Cycle Pharmaceuticals Ltd. | 20 | 2016-11-01 | 2017-11-14 |
| A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) Givosiran - Acute Intermittent Porphyria | Phase 1 / Phase 2 | Completed | Alnylam Pharmaceuticals | 16 | 2016-10-01 | 2024-03-12 |
| A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl) - Acute Intermittent Porphyria | Phase 1 | Completed | Alnylam Pharmaceuticals | 40 | 2015-05-06 | 2018-06-14 |
| Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria rAAV2/5-PBGD vector dosage 1, rAAV2/5-PBGD vector dosage 2, rAAV2/5-PBGD vector dosage 3 - Acute Intermittent Porphyria | Phase 1 | Completed | Digna Biotech S.L. | 8 | 2012-11-01 | 2014-12-18 |
| Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria heme arginate, tin mesoporphyrin - Porphyria | Phase 1 | Completed | National Center for Research Resources (NCRR) | 24 | 1998-01-01 | 2005-06-24 |
| Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria heme arginate, tin mesoporphyrin - Porphyria | Phase 1 | Completed | National Center for Research Resources (NCRR) | 20 | 1998-01-01 | 2005-06-24 |
| Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria heme arginate, tin mesoporphyrin - Porphyria | Phase 1 / Phase 2 | Completed | National Center for Research Resources (NCRR) | 59 | 1993-07-01 | 2005-06-24 |
Porphyria, Acute Intermittent (6) · Metabolism, Inborn Errors (3) · Rare Diseases (3) · Protoporphyria, Erythropoietic (2) · Coproporphyria, Hereditary (1) · Porphyria, Erythropoietic (1) · Protoporphyria, Erythropoietic, X-Linked Dominant (1) · Vomiting (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Metabolic Diseases (11) · Nutritional and Metabolic Diseases (11) · Skin Diseases (9) · Skin Diseases, Genetic (9) · Skin and Connective Tissue Diseases (9) · Digestive System Diseases (8) · Liver Diseases (8) · Porphyrias, Hepatic (8) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Pathologic Processes (3) · Signs and Symptoms (1)
givosiran (3) · heme arginate (3) · tin mesoporphyrin (3) · (4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone (1) · Chlorpromazine (1) · Ciclopirox (1) · Drug Implants (1) · Tablets (1) · afamelanotide (1)
Alnylam Pharmaceuticals (3) · National Center for Research Resources (NCRR) (3) · Atlas Molecular Pharma (1) · Clinuvel Europe Limited (1) · Cycle Pharmaceuticals Ltd. (1) · Digna Biotech S.L. (1) · Wake Forest University Health Sciences (1)
Sweden (3) · United States (3) · United Kingdom (2) · Belgium (1) · Netherlands (1) · South Africa (1) · Spain (1)
Karl Elmo Anderson (3) · Amy Simon, MD (1) · Dr. Yolandi Swart, FCPHM(SA) (1) · Herbert Bonkovsky, MD (1) · Jesus Prieto, MD (1) · Juan Ruiz, MD (1) · Nader Najafian, MD (1) · Rafael Enriquez de Salamanca, MD (1)
PMID 39363243, PMID 27212246, PMID 30726693
2016 (1)